Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All drugs

Rivoceranib + Paclitaxel

Stage Phase 2

Sponsor Asan Medical Center

Modality small molecule

Class VEGFR2 TKI (with paclitaxel)

Target VEGFR2 (KDR)

Sources

publication, as of 2026-11-07

https://pubmed.ncbi.nlm.nih.gov/40368739/

PDGFRA D842V-mutated GISTs account for about 5% to 10% of all GISTs ... Less than 1% of KIT/PDGFRA WT GISTs harbor BRAF mutations ... GISTs with NTRK gene fusions have been identified ... Other rare drivers include NF1 (somatic or germline), PIK3CA, RAS, and FGFR family translocations.

Review, Hematol Oncol Clin North Am 2025, DOI 10.1016/j.hoc.2025.04.006, PMID 40368739, text and Table 1

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT05905887

A Phase 2 Study of Paclitaxel Plus Rivoceranib in Patients With GIST With a High P-glycoprotein Expression After Failure With at Least Imatinib, Sunitinib and Regorafenib

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

NCT05905887

Registry NCT05905887

Phase Phase 2

Status Recruiting

Enrollment 48

Start 2023-09-06

Primary completion 2027-08-31

Study completion 2027-12-31

Catalyst Primary completion. 08.31.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.